ArticleEndocrine connections2026
Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RA monotherapy: a real-word analysis of the FAERS database.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the latent threat of depression and suicide/self-injury associated with the combination of glucagon-like peptide-1 agonists (GLP-1RAs) and metformin versus GLP-1RAs monotherapy, through analyzing the data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Methods: We systematically searched the FAERS database for reports on the concomitant use of GLP-1RAs and metformin compared with the GLP-1RAs monotherapy in diabetic or obese patients. Reports were categorized on the basis of the Medical Dictionary for Regulatory Activities (MedDRA) terminology. The signal was considered to be significant when the reporting odds ratio (ROR) and lower limit of 95% CI > 1, and information component (IC)025 > 0, in no less than three patients. Results: The addition of metformin increased the risk of death (38.5 vs 12.4%, P < 0.001) and hospitalization - initial or prolonged (13.5 vs 7.2%, P = 0.035) attributed to suicide/self-injury in patients who received GLP-1RAs. Furthermore, the combination of GLP-1RAs with metformin was disproportionately linked to a higher incidence of suicide/self-injury (ROR = 50.89, 95% CI: 40.79-63.48, IC025 = 5) and depression (except suicide and self-injury) (ROR = 17.28, 95% CI: 13.65-21.87, IC025 = 3.64) when compared with the GLP-1RAs monotherapy. The addition of metformin was confirmed to have shorter intervals to time-to-onset (TTO) than the GLP-1RAs monotherapy. Conclusions: The combination of GLP-1RAs and metformin is linked to a higher risk of depression and suicide/self-injury compared with the GLP-1RAs monotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.